N-acetylcysteine supplementation for the prevention of atrial fibrillation after cardiac surgery: a meta-analysis of eight randomized controlled trials

Table 4 Perioperative variables of the patients

Variable	NAC [% (n)]	Control [% (n)]	X ² value	Pvalue	Total prevalence [% (n)]
Diabetes mellitus [12, 14, 16, 17, 19]	33.8 (71/210)	30.8 (64/208)	0.442	0.506	32.3 (135/418)
Hypertension [12, 14, 16, 17, 19]	70.5 (148/210)	69.7 (145/208)	0.029	0.864	70.1 (293/418)
Congestive heart failure [17]	19.3 (17/88)	18.4 (16/87)	0.025	0.875	18.9 (33/175)
β-blocker [12, 15, 17, 19]	75.9 (167/220)	73.4 (160/218)	0.366	0.545	74.7 (327/438)
ACEI or ARB [12, 15, 17, 19]	64.1 (141/220)	60.1 (131/218)	0.744	0.388	62.1 (272/438)
Calcium channel blockers [15, 17, 19]	40.1 (65/162)	34.8 (56/161)	0.983	0.321	37.5 (121/323)

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker

ISSN: 1471-2261